Polar aromatic periphery increases agonist potency of spirocyclic free fatty acid receptor (GPR40) agonists inspired by LY2881835

Add time:08/01/2019    Source:sciencedirect.com

A series of spirocyclic compounds inspired by Eli Lilly's phase 1 antidiabetic FFA1 receptor agonist LY2881835 was designed to include polar aromatic periphery groups and explore a possibility of building additional contacts with the target near the agonist binding site. The frontrunner compound in the series (9i) was shown to be a potent (EC50 = 260 nM) FFA1 agonist with excellent aqueous (PBS) solubility and good Caco-2 permeability. The observed structure-activity relationships were rationalized by a docking study. The new series significantly expands the ligand landscape for the ongoing quest for new potent and more polar FFA1 agonists as fundamentally new class of therapeutic agents against type 2 diabetes mellitus.

We also recommend Trading Suppliers and Manufacturers of Spiro[5.5]undecane-3-carboxylic acid (cas 18244-47-8). Pls Click Website Link as below: cas 18244-47-8 suppliers

Prev:Thiobis(hexamethyldisilazane) as a new precursor for the deposition of sulfur on gold: A one-step concerted adsorption process
Next:The rates of base cleavage of substituted 2-THIENYLTRIMETHYLSILANE (cas 18245-28-8)s. AB initio calculations of the acidities of monosubstituted thiophens)